Accordingly, genetically enhancing ZNF451 expression or neutralizing PDGFB with a PDGFB-neutralizing antibody may represent a novel therapeutic strategy for PF and other fibroproliferative lung diseases. This evidence concerns the gene PDGFB and pemphigus foliaceus.